A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study
Titel:
A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study
Auteur:
Park, Sung-Soo Kim, Kihyun Kim, Seok-Jin Lee, Jae Hoon Yoon, Sung Soo Mun, Yeung Chul Lee, Je-Jung Eom, Hyeon-Seok Kim, Jin Seok Min, Chang-Ki
Verschenen in:
Biology of blood and marrow transplantation
Paginering:
Jaargang 25 (2019) nr. 7 pagina's 1312-1319
Jaar:
2019
Inhoud:
Uitgever:
American Society for Blood and Marrow Transplantation